Moreover, the application rate of SGLT-2, is only 46.4%, 40.9%, and 45.8% among patients with ASCVD, renal insufficiency (Ccr 45–90ml/min), and diabetic nephropathy respectively in 2021, and the application rate of GLP-1 is even less (Table 4). Here, GLP1R is linked to diabetic kidney disease.